INITIATOR PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.26 SEK | -1.70% |
|
+3.81% | +0.22% |
| 23/02 | Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| 21/02 | Initiator Pharma Issues New Shares for Debt Conversion | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 98.33 | 259 | 211.9 | 311.9 | 311.9 | - |
| Enterprise Value (EV) 1 | 98.33 | 238 | 172.8 | 300.8 | 251.9 | 176.9 |
| P/E ratio | -11.1 x | -12.3 x | -5.54 x | -14.1 x | 3.27 x | 19.6 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 1.94 x | 6.12 x |
| EV / Revenue | - | - | - | - | 1.56 x | 3.47 x |
| EV / EBITDA | -9.36 x | -10.3 x | -4.14 x | -11.1 x | 1.78 x | 38.5 x |
| EV / FCF | -12.2 x | -6.98 x | -5.28 x | -20.4 x | 5.86 x | 2.36 x |
| FCF Yield | -8.2% | -14.3% | -18.9% | -4.91% | 17.1% | 42.4% |
| Price to Book | 6.82 x | 7.4 x | - | - | - | - |
| Nbr of stocks (in thousands) | 27,706 | 43,772 | 52,362 | 52,916 | 52,916 | - |
| Reference price 2 | 3.549 | 5.917 | 4.046 | 5.894 | 5.894 | 5.894 |
| Announcement Date | 19/02/21 | 18/02/22 | 17/02/23 | 23/02/24 | - | - |
1DKK in Million2DKK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 161 | 51 |
| EBITDA 1 | -10.5 | -23.06 | -41.74 | -27.03 | 141.5 | 4.6 |
| EBIT 1 | -10.53 | -23.07 | -41.74 | -27.03 | 141.5 | 4.6 |
| Operating Margin | - | - | - | - | 87.89% | 9.02% |
| Earnings before Tax (EBT) 1 | -10.24 | -24.24 | -44.13 | -27.71 | 142 | 28 |
| Net income 1 | -8.697 | -21.06 | -38.46 | -22.87 | 103 | 19 |
| Net margin | - | - | - | - | 63.98% | 37.25% |
| EPS 2 | -0.3200 | -0.4800 | -0.7300 | -0.4400 | 1.800 | 0.3000 |
| Free Cash Flow 1 | -8.064 | -34.1 | -32.7 | -14.78 | 43 | 75 |
| FCF margin | - | - | - | - | 26.71% | 147.06% |
| FCF Conversion (EBITDA) | - | - | - | - | 30.39% | 1,630.43% |
| FCF Conversion (Net income) | - | - | - | - | 41.75% | 394.74% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 19/02/21 | 18/02/22 | 17/02/23 | 23/02/24 | - | - |
1DKK in Million2DKK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 21.1 | 39.1 | 24.3 | 60 | 135 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -8.06 | -34.1 | -32.7 | -14.8 | 43 | 75 |
| ROE (net income / shareholders' equity) | - | - | -111% | -101% | 173% | 15% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | 0.5200 | 0.8000 | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 19/02/21 | 18/02/22 | 17/02/23 | 23/02/24 | - | - |
1DKK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +0.22% | 44.94M | |
| +23.37% | 46.71B | |
| +48.83% | 41.8B | |
| -0.94% | 41.52B | |
| -5.86% | 29.55B | |
| +11.29% | 25.78B | |
| -20.92% | 19.26B | |
| +3.20% | 12.14B | |
| -2.67% | 12.08B | |
| +30.23% | 11.98B |
- Stock Market
- Equities
- INIT Stock
- Financials Initiator Pharma A/S